These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1395 related articles for article (PubMed ID: 32385709)
41. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012 [TBL] [Abstract][Full Text] [Related]
42. The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC. Tamiya M; Tamiya A; Okamoto N; Taniguchi Y; Nishino K; Atagi S; Hirashima T; Imamura F; Kumagai T; Suzuki H Sci Rep; 2021 May; 11(1):9629. PubMed ID: 33953280 [TBL] [Abstract][Full Text] [Related]
44. Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis. Cho BC; Kim DW; Park K; Lee JS; Yoo SS; Kang JH; Lee SY; Kim CH; Jang SH; Kim YC; Yoon HK; Han JY; Kim SW Curr Med Res Opin; 2020 Mar; 36(3):477-482. PubMed ID: 31581843 [No Abstract] [Full Text] [Related]
45. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875 [TBL] [Abstract][Full Text] [Related]
46. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876 [TBL] [Abstract][Full Text] [Related]
47. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis. Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465 [TBL] [Abstract][Full Text] [Related]
48. From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. Bordi P; Del Re M; Minari R; Rofi E; Buti S; Restante G; Squadrilli A; Crucitta S; Casartelli C; Gnetti L; Azzoni C; Bottarelli L; Petrini I; Cosenza A; Ferri L; Rapacchi E; Danesi R; Tiseo M Lung Cancer; 2019 May; 131():78-85. PubMed ID: 31027702 [TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis. Yi L; Fan J; Qian R; Luo P; Zhang J Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959 [TBL] [Abstract][Full Text] [Related]
50. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163 [TBL] [Abstract][Full Text] [Related]
51. Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR. Ariyasu R; Uchibori K; Sasaki T; Tsukahara M; Kiyotani K; Yoshida R; Ono Y; Kitazono S; Ninomiya H; Ishikawa Y; Mizukami Y; Yanagitani N; Fujita N; Nishio M; Katayama R Cancer Sci; 2021 Jun; 112(6):2371-2380. PubMed ID: 33686722 [TBL] [Abstract][Full Text] [Related]
52. Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status. Liao J; Huang Y; Gan J; Pang L; Ali WAS; Yang Y; Chen L; Zhang L; Fang W Cancer Control; 2022; 29():10732748221081360. PubMed ID: 35201951 [TBL] [Abstract][Full Text] [Related]
53. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Ahn MJ; Tsai CM; Shepherd FA; Bazhenova L; Sequist LV; Hida T; Yang JCH; Ramalingam SS; Mitsudomi T; Jänne PA; Mann H; Cantarini M; Goss G Cancer; 2019 Mar; 125(6):892-901. PubMed ID: 30512189 [TBL] [Abstract][Full Text] [Related]